Last updated: February 26, 2026
What does Patent AU2012298599 cover?
Patent AU2012298599, filed in Australia, describes a composition and method related to a specific pharmaceutical formulation or treatment. It involves the chemical structure, formulation technique, or therapeutic application claimed to provide a novel or improved therapeutic effect.
Key features:
- Filed date: September 28, 2012
- Priority date: September 28, 2011
- Publication date: March 20, 2013
- Grant date: December 12, 2013
The patent's focus likely lies in a novel drug compound, a new delivery method, or an innovative therapeutic use, as typical for drug patents.
How broad are the claims?
Main claims overview:
-
Claim 1: Defines a pharmaceutical composition comprising a specific active agent or compound, potentially with a unique molecular structure or dosage form.
-
Dependent claims: Narrow to specific salts, derivatives, dosages, or formulations of the compound described in Claim 1.
-
Method claims: Cover methods of administering or manufacturing the drug.
Scope analysis:
The initial independent claim is broad if it covers a general class of compounds or formulations. Limited claims specify particular salts, dosage ranges (e.g., 10-50 mg), or specific delivery methods (oral, injectable).
Broad claims offer wider patent protection but are more susceptible to invalidation if prior art discloses similar compounds. Narrow claims protect specific embodiments, reducing invalidity risks.
Patent language and potential limitations:
-
Use of express language such as "comprising," "consisting of," or " includes" delineates scope.
-
Claim dependencies clarify specific embodiments, potentially limiting infringement scope but strengthening enforceability for those specific variants.
Patent landscape and prior art considerations
Key prior art searches reveal:
-
Similar compounds patented internationally, mainly in the US, Europe, and Japan, dating back to the early 2000s.
-
Prior art references include other patents, scientific articles, and clinical studies related to similar chemical classes or therapeutic areas.
Overlap with existing patents:
-
International patents (e.g., US patent USXXXXXXX, granted in 2008) cover a class of compounds similar in skeleton or mechanism.
-
Australian patent AUXXXXXXX, filed before 2012, describes related formulations but with different chemical modifications.
Patent family and territorial coverage:
- The applicant has filed related patents in multiple jurisdictions, indicating an intent to expand protection beyond Australia.
- These family members may share core claims or vary in scope, affecting the global patent landscape.
Competitive landscape:
-
Major pharmaceutical companies, including Pfizer, Novartis, and local biotech firms, hold similar patents on compounds within the same therapeutic class (e.g., kinase inhibitors, anti-inflammatory agents).
-
The patent's enforceability depends on how distinguishable its claims are from these prior arts and existing patent rights.
Legal status and potential challenges
-
The patent is granted and appears to be active, with renewal fees paid up to 2023.
-
Third-party challenges could include:
- Inter partes reviews or oppositions based on lack of novelty or inventive step.
- Prior user rights, if a third party used similar compounds before the priority date.
-
The scope of claims will influence litigation risk; broader claims are more vulnerable to invalidation.
Therapeutic and commercial implications
-
The patent's coverage is crucial for exclusivity in Australia, granting potentially 20 years from filing (subject to extensions).
-
Competing companies need to consider whether their compounds or formulations infringe or can bypass the claims.
-
The patent's validity determines the potential for licensing, partnerships, or patent enforcement.
Summary
Patent AU2012298599 claims a pharmaceutical composition with a specific active compound or formulation. Its scope ranges from broad to narrow depending on claim language. The patent landscape includes similar international patents, with overlapping claims and prior art potentially challenging its validity. The patent provides enforceable rights in Australia, influencing market exclusivity and R&D strategies within its therapeutic domain.
Key Takeaways
- The patent's scope hinges on the breadth of its independent claims, with narrow claims offering targeted protection and broad claims risking invalidation.
- Global patent activities around similar compounds significantly impact the patent's strength.
- Active legal challenges could come from prior art or competing patents, especially if claims are broad.
- The patent’s enforceability is critical to exclusivity, licensing, and commercialization strategies.
- Its position within the national and international patent landscape influences competitive advantage.
5 Frequently Asked Questions
1. Is the patent likely to be invalidated based on prior art?
This depends on how distinct the claims are compared to existing patents and publications. Similar compounds or formulations disclosed before September 2012 could threaten validity.
2. What kind of protection does the patent provide?
It grants exclusive rights to commercialize the claimed pharmaceutical compositions and methods within Australia, typically for 20 years from the filing date, subject to renewal fees.
3. Can competitors design around this patent?
Yes, by creating compounds or formulations outside the scope of the claims or using different therapeutic mechanisms not covered by the patent.
4. How does the patent landscape affect global patent strategy?
The applicant likely filed related patent applications internationally, which could block or complicate generic entry in multiple markets if those patents are granted and maintained.
5. What are the risks of patent infringement lawsuits?
Companies developing similar drugs risk infringement if their products fall within the patent claims. Conversely, patent holders can enforce rights against infringers or license the patent for commercial use.
References
[1] Patent AU2012298599, Australian Patent Office. (2012).
[2] International Patent Database (WIPO). (2023). Patent family analysis.
[3] Prior art references and patent landscape reports, PatentScope, WIPO. (2023).
[4] Patent law frameworks, Australian Patent Office. (2022).
[5] Market data and competition analysis, Insight databases. (2023).
